** Shares of drugmaker Perrigo PRGO.N up 6.78% at $27
** Co reports Q1 adj. profit of $0.60 per share, above analysts' estimate of $0.55 per share, according to data compiled by LSEG
** Also reaffirms all previously provided 2025 financial targets, including adj. EPS range
** Widens 2025 net sales growth target range to 0%-3%, due to macroeconomic uncertainty, vs analysts' estimate of 1.42% growth
** "Maintaining margins and profit guidance is positive, showing management's good visibility into execution benefits. '25 is largely a self-help year" - Jefferies
** Co posts Q1 net sales of $1.04 billion
** As of last close, stock was up ~1.91% YTD
(Reporting by Megha Kumari)
((Megha.Kumari@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.